The Hypertriglyceridemia Therapeutics Market, estimated at USD 12.19 Bn in 2025, is expected to exhibit a CAGR of 5% and reach USD 17.15 Bn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
The key market players are focused on adopting growth strategies such as product launch as well as partnerships, which will drive the global hypertriglyceridemia therapeutics market during the forecast period. For instance, in December 2021, Novartis AG, a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products, announced the U.S Food and Drug Administration (FDA) approval of Leqvio (inclisiran), the first and only small interfering RNA (ribonucleic acid) (siRNA) therapy to lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one at three months.
Global Hypertriglyceridemia Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a negative impact on the global hypertriglyceridemia therapeutics market owing to the decrease in the supply chain of distribution of drugs due to lockdown. Approximately 30%-60% of the population is affected by dyslipidemia, making it one of the most prevalent conditions in healthy people. Thus, it is potentially one of the most common comorbidities in patients with COVID-19. For instance, in March 2021, according to an article published in the Journal of Clinical Medicine Insights: Endocrinology and Diabetes, the obese individuals are at a higher risk of developing dyslipidemia, insulin resistance, diabetes mellitus, hypertension, (cardiovascular diseases) CVD, and cerebrovascular disease, which are well-known predictor of poor prognosis in COVID-19 patients and dyslipidemia potentially increases mortality and severity of COVID-19. The association was stronger in patients with older age, male, and hypertension.
Global Hypertriglyceridemia Therapeutics Market: Key Developments
On June 01 2023, Amarin Pharmaceuticals Ireland Limited, a cardiovascular health pharmaceutical company, announced that its commercial partner in China, EddingPharm, a specialty pharmaceuticals company focused on clinical nutrition, oncology, antibiotics, and respiratory system therapeutics, had received regulatory approval for VASCEPA (icosapent ethyl) from China’s National Medical Products Administration (NMPA). NMPA granted approval for VASCEPA as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL).
In November 2021, Ionis Pharmaceuticals, a biotechnology company that specializes in discovering and developing RNA-targeted therapeutics, announced the initiation of CORE, the second Phase 3 clinical study of olezarsen, formerly known as IONIS-APOCIII-LRx. The CORE study is evaluating olezarsen in people with severe hypertriglyceridemia (triglyceride levels ≥ 500 mg/dL). Severe hypertriglyceridemia is a life-threatening condition associated with high levels of apoC-III and chylomicronemia, which lead to higher rates of acute pancreatitis, higher risk of cardiovascular disease, and has a high morbidity rate. Olezarsen is an investigational antisense medicine that uses Ionis' LIgand-Conjugated Antisense, (LICA), and technology. It is designed to inhibit the production of apoC-III for patients who are at risk for cardiometabolic disease and acute pancreatitis due to elevated triglyceride levels.